Well Informed. A Comprehensive Approach to Pain Management. Pain Guardian
|
|
- Adrian Anderson
- 5 years ago
- Views:
Transcription
1 Q Well Informed A Comprehensive Approach to Pain Management Use of opioids is common and necessary to support treatment for a wide variety of health related issues; however, the use of opioid medications poses risks to patients and plan sponsors alike. According to the CDC, since 2000, the death rate from drug overdoses involving opioids increased 200% (including opioid pain relievers and heroin). With the growing number of adverse events associated with the use of chronic opioids, plan sponsors need to find a way to maintain access to these medications while prioritizing patient safety and controlling costs. Since 2000, the death rate from drug overdoses involving opiods increased 200%. - CDC Pain Guardian WellDyneRx offers a comprehensive pain management strategy that supports evidence-based care and cost-effective prescribing using the following combination of methods: The WellDyneRx Pain Guardian program enables our clients to implement clinical strategies that promote safe and effective use of opioids. Recent client successes with this program include: Reducing unneeded opiate use by 12% Decreasing the amount of chronic opioid users by 36% Downgrading the number of patients that exceeded patient risk scores thresholds by 19% ering associated pain management per utilizer costs by 19% The WellDyneRx Pain Guardian programs leverage Morphine Equivalent Dose (MED) checks at the point-of-sale (prior to pharmacy dispensing) to ensure high dosage patients are being carefully monitored by their physician(s) and receiving appropriate prescriptions. (Continues on next page)
2 2017 Drug Pipeline REPORTS NOW AVAILABLE Please click the links below to access WellDyneRx s bi-annual drug pipeline reports: Biosimilar Drug Pipeline Report Brand Drug Pipeline Report Generic Drug Pipeline Report Specialty Drug Pipeline Report These publications include: Descriptions of drugs/products in development, including product highlights, place in therapy, and market impact Summaries of specialty, non-specialty, biosimilar, and generic drugs with anticipated FDA approval dates in the upcoming 12 months or in late-phase clinical trials Additional FDA actions, including rejections and indications for specific drugs If you have any questions, please contact your Account Executive. A Comprehensive Approach to Pain Management continued Compound Management Compounded treatment of pain management represents a unique opportunity to minimize the amount of opioids for patients with chronic pain. However, the safety and efficacy of some of these compounded products isn t currently available and, as such, WellDyneRx requires a medical necessity review with the prescriber prior to adjudication. We also block bulk ingredients, such as lidocaine, that drive significant plan spend. Additionally, we recommend implementing prior authorizations (PAs) for compound pain management medications that include lidocaine, baclofen, diclofenac, Seroquel (quetiapine) and ketamine to ensure patient safety; prevent fraud, waste, and abuse; and control costs. Exclusions of High Cost Topical Pain Products Pain patches and creams (excluding opioid pain patches) do not go through the same rigorous FDA approval process as most medications. These products receive FDA approval because they contain at least two FDA-approved drugs, but the final, combined medication has not been adequately tested for safety or efficacy. Manufacturers are able to charge exceptionally high ingredient costs to produce these patches and creams even though comparable OTC products are often available at a much lower price. WellDyneRx recommends excluding these topical pain products from coverage due to their high cost, limited value, and the availability of less expensive, comparable OTC alternatives. Prior Authorizations (PAs) and Quantity Level Limits (QLLs) WellDyneRx continually reviews our PA lists to ensure prescribing practices for pain medications are consistent with current evidence and guidelines. We also offer QLLs based on safety and efficacy testing for pain management. Quantities above the recommended limits are allowed on a case by case basis when evidence supports the use of higher doses. To learn more about our comprehensive Pain Management programs, contact your WellDyneRx Account Executive.
3 US Specialty Care Specialty Pharmacy Services As specialty drug costs continue to drive plan spend, US Specialty Care (USSC), WellDyneRx s wholly-owned specialty pharmacy, uses unique strategies and formulary options to help contain the cost of specialty products. USSC is widely recognized as a best-of-breed specialty pharmacy and continually yields industry-leading results for our clients: Industry-leading Specialty Adherence Rates Improving medication adherence rates can lead to a reduction in overall healthcare costs by reducing hospital readmissions and improving plan participants general health. Adherence is measured by two main industry standards: Medication Possession Ratio (MPR), which measures the percentage of time a patient has medication on hand, and Proportion of Days Covered (PDC), which measures the period covered by prescription claims for the same medication or another in its therapeutic category. Industry benchmarks indicate that 80% of patients should take at least 80% of their medication in order to be considered adherent. The average MPR of US Specialty Care patients is 92.76% and the average PDC is 90%. The average MPR of US Specialty Care patients is 92.76% and the average PDC is 90%. Drug Manufacturer Coupon Savings The Intercept TM program is a patented clinical offering designed to manage, identify, and reduce the cost of frequently prescribed specialty medications that offer a direct-to-consumer assistance program from the manufacturer. The average savings with Intercept is over $500 per medication fill. These savings are in addition to AWP discounted costs. Hepatitis C Cost Containment WellDyneRx was the first PBM in the country to adopt a lowest net cost hepatitis C (HCV) formulary, using Zepatier as our preferred product. Health outcomes for patients using Zepatier are equivalent - or better - than higher cost medications in the same class. Zepatier patients take fewer pills, making adherence to the drug regimen easier. USSC pharmacists converted 84% of the requests they received for HCV medications to the preferred product, Zepatier. Switching to Zepatier resulted in savings of over $31,000 in ingredient costs per converted patient. Switching to Zepatier resulted in savings of over $31,000 in ingredient costs per converted patient. Limited Distribution Drugs Certain medications can only be dispensed from a very limited of number of pharmacies due to the need to manage the risks associated with such products. These medications are called limited distribution products, or LDDs. On November 1, 2016, USSC began dispensing two LDDs, Aubagio and Cosentyx, which cumulatively account for 10% of our clients limited distribution drug costs. This development demonstrates the value of USSC in managing specialty conditions. Aubagio is prescribed to treat multiple sclerosis (MS) and Cosentyx is used to treat plaque psoriasis and certain types of arthritis. We are very proud to be selected as a LDD partner for these medications and look forward to expanding access to other medications soon. For additional information regarding USSC, please contact your Account Executive.
4 2017 Clinical Program Updates As part of our commitment to evidence-based care and cost-effective prescribing, WellDyneRx regularly reviews and enhances our clinical programs to ensure our solutions are comprehensive and bring the most value to our clients. We ve made the following updates to our 2017 clinical offerings: Compound Management Compounding continues to be a significant cost trend driver despite claim limits established by employers. The WellDyneRx compound management program requires medical necessity reviews with prescribers before adjudication. This year, we are excluding more bulk ingredients and compounding kits to control costs and ensure appropriate prescribing. Early Alert WellDyneRx Early Alert clients receive a monthly report that captures new utilizers of chronic medications for major disease states including high cholesterol, diabetes, asthma, and high cholesterol. We recently enhanced our reporting capabilities to include more disease states and adherence information. Intercept Through the Intercept program, WellDyneRx clients are able to maximize manufacturer copay assistance without negatively impacting plan participants. Our list of specialty medications eligible under this program expanded in 2017 to include 63 products. We will continue to add medications to this list whenever possible. Medical Specialty Cost saving measures are not unique to the pharmacy benefit. Medical Specialty is a program offering site-of-service management for medications adjudicated under the medical benefit. Pain Guardian The WellDyneRx Pain Guardian program enables our clients to implement clinical strategies that promote safe and effective use of opioids. We now offer two different program package levels to fit our clients diverse needs. Risk Stratification Tool for Pain Management Patients The WellDyneRx clinical team developed new ways to identify members being treated for pain that are considered high risk for hospitalizations and/or improper prescribing. We notify our clients as quickly as possible when these high-risk plan participants are detected so that additional support and outreach can be provided as needed. Six Month Exclusion This program blocks new medications to market for a period of six months until they can be reviewed by our P&T committee. This allows for a full clinical review by an independent team of physicians prior to placement on our formularies and implementation of prior authorization criteria. For more information regarding any of our clinical programs, please contact your Account Executive.
5 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Tecentriq (Genentech) atezolizumab Bladder cancer Tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (muc) who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery. The recommended dose of Tecentriq is 1200mg as an intravenous (IV) infusion over 60 minutes every 3 weeks. Lartruvo (Eli Lilly) olaratumab Soft tissue sarcoma Lartruvo is the first monoclonal antibody to be indicated for treating adults with soft tissue sarcomas (STS). Recommended dosing for Lartruvo is on 21-day cycles with 15 mg/kg given as a 60-minute IV infusion on day 1 and day 8. Doxorubicin is given along with Lartruvo for the first eight cycles. Treatment continues until the patient can no longer tolerate side effects or until the cancer ceases to respond. In the open-label, Phase II JGDG clinical trial, median overall survival was nearly one year longer among patients using Lartruvo and doxorubicin than among patients on doxorubicin alone. Zinplava (Merck) bezlotoxumab Clostridium difficile (C. diff) Zinplava is a monoclonal antibody used as ancillary treatment to decrease the likelihood of a relapse with a specific bacterial infection. It is approved by the FDA for use in combination with an antibacterial for preventing recurrence of Clostridium difficile (C. diff) infection for patients who are at least 18 years old, who are undergoing antibacterial treatment for C. diff and who are at high risk of acquiring the infection again. Recommended dosing is 10mg/kg given as a single IV infusion over a one-hour period. It must be used in conjunction with an antibacterial agent.
6 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Bonjesta TM (Duchesnay) doxylamine/ pyridoxine Nausea and vomiting associated with pregnancy Bonjesta extended-release tablets combine 20mg each of an antihistamine (doxylamine) and a form of vitamin B6 (pyridoxine). It is indicated to treat nausea and vomiting associated with pregnancy when conservative treatment, such as dietary modification, is not effective. If the recommended dose of one tablet at bedtime does not control symptoms, an additional tablet may be added in the morning. No more than two tablets should be taken per day. Moderate Vemlidy (Gilead) tenofovir alafenamide Chronic hepatitis B Vemlidy is indicated to treat patients who have chronic hepatitis B that has not yet progressed to cirrhosis. Because Vemlidy maintains relatively constant blood levels, it is effective at a lower dose (25mg/day) than Viread (tenofovir disoproxil). Consequently, Vemlidy does not cause as many side effects, particularly on bones and in kidneys. Recommended dosing is one tablet daily along with a meal or snack. Intrarosa (EndoCeutics) prasterone Vulvovaginal atrophy Intrarosa vaginal inserts treat vulvovaginal atrophy (VVA). This is a condition that makes having sex painful and difficult for many women after menopause due to alkalinity, dryness, irritation and thinning of the female lower reproductive tract. Also, widely known as DHEA, prasterone is a natural steroid hormone produced mainly by the adrenal glands and then converted into estrogens and androgens. Biological prasterone production gradually decreases around age 30. At menopause, estrogen drops even further. Intrarose is the first prescription prasterone to be FDA-approved. It will be available as 6.5mg vaginal inserts that are used once daily. Moderate
7 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Xultophy (Novo Nordisk) insulin degludec / liraglutide Diabetes Xultophy combines the company s Tresiba (insulin degludec) and Victoza (liraglutide) into a once-daily subcutaneous injection. Xultophy is indicated for the treatment of adults with type 2 diabetes that are inadequately controlled on basal (long-acting) insulin or GLP-1 agonists as monotherapy. High Soliqua (Sanofi) Insulin glargine / lixisenatide Diabetes Soliqua is a fixed-dose combination product of 100 units per ml of Lantus (insulin glargine) and 33 mcg per ml of Adlyxin (lixisenatide) and comes in a 3 ml single-patient use pen. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Soliqua is dosed once-daily by subcutaneous injection and the recommended starting dose is 15 units. High Synjardy XR (Eli Lilly / Boehringer Ingelheim) Empagliflozin / metformin extended-release Diabetes Synjardy XR is a long-acting, once daily medication that improves glycemic control for adults with type 2 diabetes mellitus. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a drug class that blocks reabsorption of glucose in the kidneys. Metformin lowers glucose production and raises insulin utilization. High Eucrisa (Pfizer) crisaborole Eczema Eucrisa 2% ointment is the first topical phosphodiesterase 4 (PDE-4) inhibitor indicated to treat eczema in patients two years of age and older. Atopic dermatitis is a common form of eczema. Eucrisa is applied to the affected area of skin twice a day. Moderate
8 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Rubraca (Clovis Oncology, Inc.) rucaparib Ovarian cancer Rubraca is indicated for ovarian cancer that has progressed despite at least two chemotherapy treatments and that has a deleterious BRCA genetic mutation. Rubraca is an oral drug with recommended max dosing of 600mg twice a day until the cancer worsens or the patient cannot take the drug any longer. Two different strengths of Rubraca were approved: 200 mg and 300 mg. Spinraza (Biogen / Ionis) nusinersen Spinal muscular atrophy (SMA) Spinraza is the first drug indicated to treat spinal muscular atrophy (SMA), a rare genetic condition that causes increasing weakness in muscles. Spinraza will be given directly into the fluid around the spinal cord by a healthcare provider who is trained to perform spinal procedures. Recommended dosing is three 12mg doses administered at two-week intervals, followed by a fourth dose one month after the third; and then by one dose every four months.
Kentucky Department for Medicaid Services Drug Review and Options for Consideration
Drug Review and The following table lists the Agenda items scheduled, as well as the, to be presented and reviewed at the March 16, 2017 meeting of the Pharmacy and Therapeutics Advisory Committee. Single
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationInsulins: Prices, Rebates, and Other Factors Influencing Costs. May 2018
Insulins: Prices, Rebates, and Other Factors Influencing Costs May 2018 Introduction: Types of Insulin Types of Insulin Rapid-acting: Usually taken before a meal to cover the blood glucose elevation from
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationNew Drugs of /23/2017. Disclosure. Learning Objectives: Technicians
New Drugs of 2016 Kendra Ernste, Pharm.D 2018 Candidate and Khia Warzecha, Pharm.D 2019 Candidate Disclosure We have had no financial relationship over the past 12 months with any commercial sponsor with
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationDRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde
WellDyneRx 34% 1 2% Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu HIV Pain/inflammation High Blood Choles Attention Disorde Inflammatory Con Diabetes MS Oncology Asthma/COPD High
More informationI have no financial incentives or conflicts of interest to disclose for this presentation.
Jacob Lenzmeier, PharmD Resident Pharmacist-CentraCare Health November 9, 2017 1 I have no financial incentives or conflicts of interest to disclose for this presentation. 2 1 Review the mechanism of action,
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More information2017 New Drug Update. Robert Lipsy PharmD, FASHP Southwest Clinical Pharmacy Seminar February 25 and Tucson, Az. Conflicts of Interest None
2017 New Drug Update Robert Lipsy PharmD, FASHP Southwest Clinical Pharmacy Seminar February 25 and 26 2017 Tucson, Az. Conflicts of Interest None New Drugs 2016 1 New Drugs December 2016 New Drugs December
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationPrescription Benefit Management. Eric Cannon, PharmD, FAMCP
Prescription Benefit Management Eric Cannon, PharmD, FAMCP Agenda Drugs as a Share of Health Spending Top Drugs of 2016 Management Interventions and Strategies Specialty Pharmacy, Generics and Biologics
More informationNew Drug Update 2017 Brooke Roe, PharmD, BCPS Katie Wenstrom, PharmD
New Drug Update 2017 Brooke Roe, PharmD, BCPS Katie Wenstrom, PharmD Objectives: 1. Identify significant therapeutic agents that were granted U.S. Food and Drug Administration approval in the past year
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: LA.PST.14 Effective Date: 03.18 Last Review Date: 3.18 Line of Business: Medicaid Revision Log 1Revision Log 1Revision
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: HIM Revision Log See Important Reminder
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationAdded, Removed or Changed. Date of Change. No Change
One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationJOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE
JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE PASBO S STATEWIDE DATA STRATEGY WITH INNOVU PASBO 62 ND ANNUAL CONFERENCE AND EXHIBITS, PITTSBURGH 1 DATA STRATEGY PLATFORM 2 1 WHAT ARE
More informationCollaborative Practice Agreement
Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationIntensification of Diabetic Therapy. Case studies
Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,
More informationRUBRACA (rucaparib camsylate) oral tablet
RUBRACA (rucaparib camsylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationConverting lantus to humalog 75 25
P ford residence southampton, ny Converting lantus to humalog 75 25 This page includes the following topics and synonyms: Insulin Dosing in Type 2 Diabetes, Insulin Dosing in Type II Diabetes. Thiazide
More informationCoventry Health Care of Georgia, Inc.
Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan
More informationMedication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace See Important
More information2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan
2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More information2018 Travelers Prescription Drug Plan High Deductible + HSA Plan
2018 Travelers Prescription Drug Plan High Deductible + HSA Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that section National Preferred Formulary
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More information2017 Drug Trends Series
2017 Drug Trends Series Part 1 Evaluating the traditional view Retail and mail-order prescriptions Published April 2018 1 2017 Drug Trends Series Traditional View First Script A year of important progress
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationShining a Light on MEDs Understanding morphine equivalent dose
Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace
More information2017 Drug Trend Report Commercial Medicare Medicaid Exchanges
2017 Drug Trend Report Commercial Medicare Medicaid Exchanges Leading the way for patients and plans Our clients place a great deal of trust in Express Scripts. They ask us to care for their plan members
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationSpecialty Drugs in Workers Compensation
Specialty Drugs in Workers Compensation A GUIDE FOR CLAIMS HANDLERS Specialty Drugs Specialty drugs have been developed in response to demand for specialized medications for complex medical conditions.
More informationDrug Updates for Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Center for Family Medicine Cleveland Clinic Akron General
Drug Updates for 2016 Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Center for Family Medicine Cleveland Clinic Akron General Objectives 1. Name the new pharmaceutical agents available
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationManaging Opioid Overutilization Challenges
One Source. Lower Cost. Better Care. Managing Opioid Overutilization Challenges A LOOK AT REDUCING OPIOID OVERUTILIZATION BY 36 PERCENT Copyright 2017 MedImpact Healthcare Systems, Inc. All rights reserved.
More informationUpdate to HMO Drug Formulary Tier Definitions. February 8, 2018
Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works
More informationPrescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks
Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks Patient Health and Safety Guidelines Prescription Medications Policy Update / April 2017 In connection
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationPHARMACY BENEFITS MANAGER
PHARMACY BENEFITS MANAGER CU GME Benefits Office Prescriptions should be obtained at participating pharmacies using your Benefits ID card. A list of participating pharmacies may be obtained by calling
More informationDiabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services
Diabetes Meds Update 2016 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Disclaimer and Important Info This content is for educational purposes only. Please see Package
More informationKEEPING SAFE WITH INSULIN THERAPY
KEEPING SAFE WITH INSULIN THERAPY kk WHY IS THIS LEAFLET FOR YOU? Insulin treatment improves the quality of life in many people and saves the lives of others. It is used to lower blood glucose levels.
More informationOpioid analgesics have the potential to affect every major body system. Meet Tom.
Opioid analgesics have the potential to affect every major body system. Meet Tom. This is Tom. The side effects of opioid analgesics often outweigh the benefits of their painrelieving properties. To illustrate
More informationDisclosures. Pharmacist Objectives. Technician Objectives. Definitions. Definitions. New Drug & Therapies Update 11/2/17. First-in-Class Drug
Disclosures New Drug & Therapies Update No relevant conflicts of interest to disclose No off-label indications will be presented Nicholas Cox, PharmD November 4, 2017 Intensive Outpatient Clinic, University
More information4/2/2018. Easing the pharmacy experience and stretching the diabetes dollar. Alyson Blum, PharmD, CDE. I have no conflicts of interest to disclose
Easing the pharmacy experience and stretching the diabetes dollar. Alyson Blum, PharmD, CDE Clinical Pharmacist in Obstetrics Center for Maternal Fetal Medicine at Sacred Heart Medical Center Clinical
More informationFlexRx 6-Tier. SM Pharmacy Benefit Guide
FlexRx 6-Tier SM Pharmacy Benefit Guide Welcome to FlexRx The AllWays Health Partners FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many
More informationPERSPECTIVE THERXPIPELINE
ON PERSPECTIVE THERXPIPELINE Understanding changes in the medication market and their impact on cost and care. EnvisionRx continuously monitors the drug pipeline. As treatment options change, we evaluate
More informationKEEP LOVING. Because HIV doesn t change who you are.
KEEP LOVING. Because HIV doesn t change who you are. BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in certain adults. BIKTARVY does not cure HIV-1 or AIDS. Please
More informationOpioid epidemic and PEHP
Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationWell Informed. WellManaged - Diabetes INTRODUCING: WellDyneRx plan participants are eligible to receive a free One Touch System glucose meter
Q4 2 0 1 7 Well Informed With 2017 winding down, we re taking stock of how we performed throughout the year and setting goals for 2018. Towards that end, we recently distributed our annual Client Satisfaction
More informationType 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research "Type 1 diabetes market size was valued at USD 25.52 billion in 2016 and is expected to exhibit rewarding
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationCoverage Period: 01/01/ /31/2018 Coverage for: Individual and/or Family Plan: Healthy Rewards HSA
This is only a summary of your GatorCare pharmacy benefits. If you would like detail about your coverage and costs, you can get the complete terms in the policy or plan document at gatorcare.magellanrx.com/member
More informationLEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector
LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationPACKAGE LEAFLET: Information for the user. METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride)
PACKAGE LEAFLET: Information for the user METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride) Read this leaflet carefully before you start taking this medicine. - Keep this
More information8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations
UNRAVELING THE CROWED INSULIN SCENE A Practical Overview of Insulin Focusing on New Insulin Preparations Patricia Garnica MS, ANP-BC, CDE, CDTC North Shore University Hospital, Manhasset, N.Y. October
More informationDrug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists
Texas Vendor Drug Program Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists Publication History Developed February 2006. Revised September 2018; September 2016; June 2015; October 2013; December
More informationPharmacy benefit guide
FlexRx SM 5-Tier Pharmacy benefit guide 1 Welcome to FlexRx The NHP FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many common medications
More informationPBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.
Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationThe Opioid Epidemic and How It is Impacting the Workplace. July 24, 2018
The Opioid Epidemic and How It is Impacting the Workplace July 24, 2018 In 2016 CDC reports a 300% increase in opioid prescription sales since 1999 without an overall change in reported pain National Safety
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationDrug Guide. April New Specialty Drug Approvals. New Formulations for Existing Drugs
April 2013 The MedTrak Drug Guide provides a monthly update on recent approvals by the Food and Drug Administration (FDA). Use the chart below as a valuable reference tool. Additional detailed information
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationA COMPREHENSIVE APPROACH TO MANAGING DIABETES
A COMPREHENSIVE APPROACH TO MANAGING DIABETES Programs and services to help individuals avoid costly complications and improve outcomes 2 0 1 8 ENTER Supporting each member with targeted guidance and services.
More informationCase Study. GlucosePATH shows the way to improved outcomes and $1.1MM in employer drug cost savings
Case Study GlucosePATH shows the way to improved outcomes and $1.1MM in employer drug cost savings Background A self-insured company has 600 employees with Type 2 Diabetes The company asked if GlucosePATH
More informationCentene Pharmacy Therapeutics Committee Therapeutic Class Matrix Summary Table 3Q18
HGPI Therapeutic Class Review Recommendation 01 Penicillins Based on the available clinical evidence, there are no utilization management recommendations to be made at this time. 02 Cephalosporins Based
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationBlue Cross of Idaho Addresses State s Opioid Issue
Blue Cross of Idaho Addresses State s Opioid Issue BY THE NUMBERS - Opioid Management page 3 THE PROBLEM - How Preventing Pain Hurt Us page 4 THE SOLUTIONS - Idaho State Board Of Pharmacy Prescription
More informationManagement: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018
Management: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018 Disclosures I have no Objectives Use a case-based format to discuss diabetes management pearls Discuss
More informationwellinformed APRIL 2016
wellinformed APRIL 2016 New FDA-Approved Drugs The following drug products were recently approved by the U.S. Food and Drug Administration (FDA): Zemplar Paricalcitol Parathyroid hormone Sernivo Betamethasone
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.19 Subject: SGLT2 Inhibitors Page: 1 of 5 Last Review Date: December 3, 2015 SGLT2 Inhibitors Description
More informationFor patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH
For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority
More informationCurrent and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
More informationGetting started on Otezla
Getting started on Otezla Your guide to starting and staying on treatment Otezla (apremilast) is a prescription medicine approved for the treatment of patients with moderate to severe plaque psoriasis
More informationSUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy
SUBHEAD GOES HERE Addressing Tennessee s Opioid Crisis Natalie A. Tate, PharmD Vice President, Pharmacy Our opioids story Our approach Our response to neonatal abstinence syndrome Facts and faces of opioid
More informationCoverage Period: Coverage for: Plans: This is only a summary of your GatorCare pharmacy benefits. Coinsurance: you your Dependent Copayment: you
This is only a summary of your GatorCare pharmacy benefits. If you would like detail about your coverage and costs, you can get the complete terms in the policy or plan document at gatorcare.magellanrx.com/member
More informationManaged Care Pushes for Safer Opioid Oversight
Page 1 of 6 Clinical AUGUST 11, 2017 Managed Care Pushes for Safer Opioid Oversight High-risk pain Rx eyed Denver Health systems haven t escaped the nation s ongoing opioid crisis, as evidenced by surging
More informationQ&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend
Learn More Q&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend Iowa and South Dakota Pharmacy Benefit Plans This document answers questions regardingupcoming
More informationUnderstanding Your Patient Care Opportunity Report (PCOR)
Understanding Your Patient Care Opportunity Report (PCOR) Use your January/February 208 PCOR to help improve performance on Medicare Part D Clinical Star Ratings measures. Your January/February 208 Patient
More information